Dataset Information


Predictors of response to pegylated interferon in chronic hepatitis B: a real-world hospital-based analysis.

ABSTRACT: Information on the efficacy of pegylated interferon (PEG-IFN) treatment of chronic hepatitis B (CHB) patients and predictors of the response based on real-world data is limited. Consecutive 201 patients who underwent PEG-IFN treatment for CHB were reviewed. A virological response (VR) was defined as a serum HBV DNA of <2000?IU/mL, and a combined response (CR) was defined a VR accompanied by serological response for hepatitis B e antigen (HBeAg)-positive CHB. For HBeAg-positive CHB patients, the HBeAg seroconversion rate and CR rate were 30.5% and 21.2% at 48 weeks after end of treatment (EOT), respectively. Baseline alanine aminotransferase (ALT) level was associated with HBeAg seroconversion, while baseline hepatitis B s antigen (HBsAg) levels of <250?IU/mL and HBV DNA <2.5?×?10(7)?IU/mL were strongly associated with sustained off-treatment CR. For HBeAg-negative CHB, the VR rates were 85.5%, and 27.7% at EOT, and 48 weeks after EOT, respectively; a baseline HBsAg <1,250?IU/mL was associated with sustained off-treatment VR. PEG-IFN treatment has durable HBeAg seroconversion in HBeAg-positive CHB, but results in a high risk of relapse among HBeAg-negative CHB patients. Pre-treatment HBsAg level is an important predictor of VR in CHB patients undergoing PEG-IFN treatment.


PROVIDER: S-EPMC4941731 | BioStudies | 2016-01-01

REPOSITORIES: biostudies

Similar Datasets

2013-01-01 | S-EPMC3790882 | BioStudies
2019-01-01 | S-EPMC6783682 | BioStudies
1000-01-01 | S-EPMC5838532 | BioStudies
2016-01-01 | S-EPMC4752655 | BioStudies
1000-01-01 | S-EPMC4468690 | BioStudies
2019-01-01 | S-EPMC6590282 | BioStudies
1000-01-01 | S-EPMC4555327 | BioStudies
2018-01-01 | S-EPMC5862996 | BioStudies
2017-01-01 | S-EPMC5645387 | BioStudies
1000-01-01 | S-EPMC5318891 | BioStudies